Related Experiment Video

Updated: Jun 28, 2025

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient
07:16

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient

Published on: November 30, 2022

3.2K

[Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19]

Alejandro Muñoz-Jiménez1, Esteban Rubio-Romero1, José Luis Marenco de la Fuente2

  • 1Servicio de Reumatología, Hospital Universitario Virgen del Rocío, Sevilla, España.

Reumatologia Clinica
|April 15, 2024
PubMed

Insights

Severe COVID-19 infection causes lung damage via an inflammatory cytokine storm. Anakinra, an IL-1ß blocker, may control this acute respiratory distress syndrome (ARDS) in patients.

Area of Science:

  • Immunology
  • Pulmonology
  • Virology

Context:

  • SARS-CoV-2 (COVID-19) infection leads to significant lung damage.
  • Acute Respiratory Distress Syndrome (ARDS) is a severe complication driven by inflammation.
  • The NLRP3 inflammasome and subsequent cytokine storm are key pathological mechanisms.

Purpose:

  • To explore the potential of Anakinra in managing COVID-19-induced ARDS.
  • To investigate Anakinra's role in mitigating the cytokine storm associated with severe COVID-19.

Summary:

  • COVID-19 infection triggers an inflammatory response in the lungs, leading to ARDS.
  • This inflammatory process involves the NLRP3 inflammasome and a cytokine storm, with IL-1ß being a major mediator.
  • Anakinra, a biological drug, inhibits IL-1ß and is proposed as a therapeutic option for COVID-19-related ARDS.

Impact:

  • Anakinra may offer a targeted treatment to reduce lung inflammation and alveolar destruction in severe COVID-19.
  • This approach could potentially improve outcomes for patients suffering from COVID-19-induced ARDS.
  • Further clinical investigation of Anakinra for COVID-19 ARDS is warranted.
Keywords:
Acute respiratory distress syndromeAnakinraCOVID-19IL-1ßInflamosome

More Related Videos

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

2.8K
A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects05:46

A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects

Published on: May 4, 2021

4.8K

Related Concept Videos

Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
218
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
204
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
428
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
136
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
391
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
198